financetom
Business
financetom
/
Business
/
Mobile data services firm uCloudlink's Q3 revenue down 16%, misses estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mobile data services firm uCloudlink's Q3 revenue down 16%, misses estimates
Nov 12, 2025 1:07 AM

Overview

* uCloudlink Q3 revenue declines 16% yr/yr, missing analyst expectations

* Net income for Q3 rises to $9.3 mln from $3.4 mln last year

* Company highlights strategic investments and new product launches for future growth

Outlook

* uCloudlink expects Q4 2025 revenue between $22.0 mln and $26.5 mln

* Company revises 2025 full-year revenue forecast to $81.3 mln-$85.8 mln

* uCloudlink cites macroeconomic challenges impacting industry outlook

Result Drivers

* INTERNATIONAL DATA CONNECTIVITY - Revenue growth in international data connectivity services driven by expansion of China's outbound travel market

* USER ENGAGEMENT - Significant growth in daily and monthly active terminals, particularly in GlocalMe IoT and SIM businesses

* PRODUCT LAUNCHES - Launch of new products like PetPhone and MeowGo G40 Pro as strategic growth engines

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $21.10 $22.10

Revenue mln mln (1

Analyst)

Q3 $700,000

Adjusted

Net

Income

Q3 $1.40

Adjusted mln

EBITDA

Q3 Gross $11.30

Profit mln

Q3 $9.20

Income mln

from

Operatio

ns

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the wireless telecommunications services peer group is "buy"

* Wall Street's median 12-month price target for Ucloudlink Group Inc ( UCL ) is $8.00, about 72% above its November 11 closing price of $2.24

* The stock recently traded at 100 times the next 12-month earnings vs. a P/E of 118 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Panama Signals It's Ready to Negotiate On Shuttered First Quantum Copper Mine
Market Chatter: Panama Signals It's Ready to Negotiate On Shuttered First Quantum Copper Mine
Mar 14, 2025
08:57 AM EDT, 03/14/2025 (MT Newswires) -- First Quantum Minerals Ltd. ( FQVLF ) was cleared to begin shipping out stockpiled copper in Panama, the latest sign authorities may be willing to negotiate a restart of the company's giant shuttered mine, Bloomberg News is reporting Friday. It noted Panama's President Jose Raul Mulino said Thursday he has authorized the export...
Scotiabank Previews Carney Likely First Actions as Canada's Prime Minister
Scotiabank Previews Carney Likely First Actions as Canada's Prime Minister
Mar 14, 2025
08:55 AM EDT, 03/14/2025 (MT Newswires) -- Mark Carney will be officially sworn in as prime minister of Canada at 11 a.m. ET Friday, noted Scotiabank. Among his first actions on the job will be to kill the carbon tax and then secure meetings with key international leaders, said the bank. Carney's reportedly off to Europe next week to build...
DocuSign's IAM Driving Growth Needs More 'Proof Points,' RBC Says
DocuSign's IAM Driving Growth Needs More 'Proof Points,' RBC Says
Mar 14, 2025
08:57 AM EDT, 03/14/2025 (MT Newswires) -- DocuSign ( DOCU ) reported solid fiscal Q4 results with strong billings growth, but the case for its Intelligent Agreement Management product driving growth needs more clarity, RBC Capital Markets said in a Thursday note. The company's outperformance in billings, which was driven by early renewals, along with increasing usage, were encouraging data...
Palisade Bio Begins Dosing Ulcerative Colitis Patients in PALI-2108 Trial
Palisade Bio Begins Dosing Ulcerative Colitis Patients in PALI-2108 Trial
Mar 14, 2025
08:57 AM EDT, 03/14/2025 (MT Newswires) -- Palisade Bio ( PALI ) said Friday it began dosing ulcerative colitis patients in the final cohort of its phase 1a/b study of PALI-2108. The company said it had completed five single ascending dose cohorts and three of four multiple ascending dose cohorts, with no serious adverse events or treatment-related adverse events tied...
Copyright 2023-2026 - www.financetom.com All Rights Reserved